Global Brain Biomarker

Brain Biomarker Comprehensive Study by Type (Biomarker Test Kits, Biomarker Analyzers), Application (Diagnosis, Monitoring, Detect the Patients Response, Other), Disease (Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Stroke, Others), End User (Hospitals, Research Institutes, Surgical Centres, Diagnostic Centres, Others) Players and Region - Global Market Outlook to 2027

Brain Biomarker Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 12.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Brain Biomarker
Brain biomarkers which are generally the molecules that signify the existence of a disorder or illness in the brain—are becoming more important for verifying diagnosis, selecting the right therapies, and tracking disease progression. According to the National Institutes of Health, a Biomarker is “a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic responses to a therapeutic intervention” A biomarker must be able to detect fundamental features of neuropathology and it also to be validated among confirmed cases. With the increasing investment in brain-related disorders; the demand for brain biomarkers is also increasing.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
CAGR12.8%


Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Advanced Brain Monitoring, Electrical Geodesics (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers (Germany), GE Healthcare (United States), NeuroVista (United States), Nexus-DX, Qiagen N.V. (Germany), Lifesign LLC. (United States) and BrainScope are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Brain Biomarker market by Type (Biomarker Test Kits and Biomarker Analyzers), Application (Diagnosis, Monitoring, Detect the Patients Response and Other) and Region.



On the basis of geography, the market of Brain Biomarker has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease, the sub-segment i.e. Alzheimer’s Disease will boost the Brain Biomarker market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Brain Biomarker market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
On 2nd July 2020, Magstim, a global leader in TMS, has announced the acquisition of Electrical Geodesics, Inc. (EGI)'s portfolio from Royal Philips, a global leader in health technology. In brain science, EGI develops non-invasive multimodal technologies to monitor brain function and deliver transcranial electrical stimulation. Magstim will purchase EGI's hardware, applications, and sensor network infrastructure, and will take over worldwide distribution, operation, and support immediately. Philips will continue to assist in the process until the end of 2020.
On 20th April 2021, At the American Academy of Neurology's (AAN) annual conference, Advanced Brain Monitoring, Inc. announced the discovery of two novel sleep biomarkers related to neurodegenerative disease. The first biomarker, Non-REM Sleep with Hypertonia, was reported to be significantly higher in patients with Parkinson's disease, while the second biomarker, Atypical Stage N3 Sleep, was found to be significantly higher in patients with dementia caused by synucleinopathies.


Market Drivers
  • Need of Brain Biomarkers to Track Brain Health
  • Need of Brain Biomarker to Track the Disease Progression in The Brain
  • The demand for Brain Biomarkers for Research Purposes

Opportunities
  • Growing Medical Investment in Brain Related Diseases Will Increase the Demand of Brain Biomarkers
  • Emerging Demand for Brain Biomarkers as They Are Less Biased Than Alternatives

Restraints
  • Biomarkers Are Prone to Laboratory Errors

Challenges
  • Measurement Errors in Biomarkers Are Challenging to Reduce
  • High Cost of Biomarker Development


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Brain Biomarker Providers, Government Regulatory and Research Organizations, End-Use Industries and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Biomarker Test Kits
  • Biomarker Analyzers
By Application
  • Diagnosis
  • Monitoring
  • Detect the Patients Response
  • Other
By Disease
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Huntington’s Disease
  • Stroke
  • Others

By End User
  • Hospitals
  • Research Institutes
  • Surgical Centres
  • Diagnostic Centres
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Need of Brain Biomarkers to Track Brain Health
      • 3.2.2. Need of Brain Biomarker to Track the Disease Progression in The Brain
      • 3.2.3. The demand for Brain Biomarkers for Research Purposes
    • 3.3. Market Challenges
      • 3.3.1. Measurement Errors in Biomarkers Are Challenging to Reduce
      • 3.3.2. High Cost of Biomarker Development
    • 3.4. Market Trends
      • 3.4.1. Growing Investment in The Research of Biomarkers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Brain Biomarker, by Type, Application, Disease, End User and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Brain Biomarker (Value)
      • 5.2.1. Global Brain Biomarker by: Type (Value)
        • 5.2.1.1. Biomarker Test Kits
        • 5.2.1.2. Biomarker Analyzers
      • 5.2.2. Global Brain Biomarker by: Application (Value)
        • 5.2.2.1. Diagnosis
        • 5.2.2.2. Monitoring
        • 5.2.2.3. Detect the Patients Response
        • 5.2.2.4. Other
      • 5.2.3. Global Brain Biomarker by: Disease (Value)
        • 5.2.3.1. Alzheimer’s Disease
        • 5.2.3.2. Parkinson’s Disease
        • 5.2.3.3. Huntington’s Disease
        • 5.2.3.4. Stroke
        • 5.2.3.5. Others
      • 5.2.4. Global Brain Biomarker by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Research Institutes
        • 5.2.4.3. Surgical Centres
        • 5.2.4.4. Diagnostic Centres
        • 5.2.4.5. Others
      • 5.2.5. Global Brain Biomarker Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Brain Biomarker: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Advanced Brain Monitoring
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Electrical Geodesics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Siemens Healthineers (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GE Healthcare (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NeuroVista (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nexus-DX
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Qiagen N.V. (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Lifesign LLC. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. BrainScope
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Brain Biomarker Sale, by Type, Application, Disease, End User and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Brain Biomarker (Value)
      • 7.2.1. Global Brain Biomarker by: Type (Value)
        • 7.2.1.1. Biomarker Test Kits
        • 7.2.1.2. Biomarker Analyzers
      • 7.2.2. Global Brain Biomarker by: Application (Value)
        • 7.2.2.1. Diagnosis
        • 7.2.2.2. Monitoring
        • 7.2.2.3. Detect the Patients Response
        • 7.2.2.4. Other
      • 7.2.3. Global Brain Biomarker by: Disease (Value)
        • 7.2.3.1. Alzheimer’s Disease
        • 7.2.3.2. Parkinson’s Disease
        • 7.2.3.3. Huntington’s Disease
        • 7.2.3.4. Stroke
        • 7.2.3.5. Others
      • 7.2.4. Global Brain Biomarker by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Research Institutes
        • 7.2.4.3. Surgical Centres
        • 7.2.4.4. Diagnostic Centres
        • 7.2.4.5. Others
      • 7.2.5. Global Brain Biomarker Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Brain Biomarker: by Type(USD Million)
  • Table 2. Brain Biomarker Biomarker Test Kits , by Region USD Million (2016-2021)
  • Table 3. Brain Biomarker Biomarker Analyzers , by Region USD Million (2016-2021)
  • Table 4. Brain Biomarker: by Application(USD Million)
  • Table 5. Brain Biomarker Diagnosis , by Region USD Million (2016-2021)
  • Table 6. Brain Biomarker Monitoring , by Region USD Million (2016-2021)
  • Table 7. Brain Biomarker Detect the Patients Response , by Region USD Million (2016-2021)
  • Table 8. Brain Biomarker Other , by Region USD Million (2016-2021)
  • Table 9. Brain Biomarker: by Disease(USD Million)
  • Table 10. Brain Biomarker Alzheimer’s Disease , by Region USD Million (2016-2021)
  • Table 11. Brain Biomarker Parkinson’s Disease , by Region USD Million (2016-2021)
  • Table 12. Brain Biomarker Huntington’s Disease , by Region USD Million (2016-2021)
  • Table 13. Brain Biomarker Stroke , by Region USD Million (2016-2021)
  • Table 14. Brain Biomarker Others , by Region USD Million (2016-2021)
  • Table 15. Brain Biomarker: by End User(USD Million)
  • Table 16. Brain Biomarker Hospitals , by Region USD Million (2016-2021)
  • Table 17. Brain Biomarker Research Institutes , by Region USD Million (2016-2021)
  • Table 18. Brain Biomarker Surgical Centres , by Region USD Million (2016-2021)
  • Table 19. Brain Biomarker Diagnostic Centres , by Region USD Million (2016-2021)
  • Table 20. Brain Biomarker Others , by Region USD Million (2016-2021)
  • Table 21. South America Brain Biomarker, by Country USD Million (2016-2021)
  • Table 22. South America Brain Biomarker, by Type USD Million (2016-2021)
  • Table 23. South America Brain Biomarker, by Application USD Million (2016-2021)
  • Table 24. South America Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 25. South America Brain Biomarker, by End User USD Million (2016-2021)
  • Table 26. Brazil Brain Biomarker, by Type USD Million (2016-2021)
  • Table 27. Brazil Brain Biomarker, by Application USD Million (2016-2021)
  • Table 28. Brazil Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 29. Brazil Brain Biomarker, by End User USD Million (2016-2021)
  • Table 30. Argentina Brain Biomarker, by Type USD Million (2016-2021)
  • Table 31. Argentina Brain Biomarker, by Application USD Million (2016-2021)
  • Table 32. Argentina Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 33. Argentina Brain Biomarker, by End User USD Million (2016-2021)
  • Table 34. Rest of South America Brain Biomarker, by Type USD Million (2016-2021)
  • Table 35. Rest of South America Brain Biomarker, by Application USD Million (2016-2021)
  • Table 36. Rest of South America Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 37. Rest of South America Brain Biomarker, by End User USD Million (2016-2021)
  • Table 38. Asia Pacific Brain Biomarker, by Country USD Million (2016-2021)
  • Table 39. Asia Pacific Brain Biomarker, by Type USD Million (2016-2021)
  • Table 40. Asia Pacific Brain Biomarker, by Application USD Million (2016-2021)
  • Table 41. Asia Pacific Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 42. Asia Pacific Brain Biomarker, by End User USD Million (2016-2021)
  • Table 43. China Brain Biomarker, by Type USD Million (2016-2021)
  • Table 44. China Brain Biomarker, by Application USD Million (2016-2021)
  • Table 45. China Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 46. China Brain Biomarker, by End User USD Million (2016-2021)
  • Table 47. Japan Brain Biomarker, by Type USD Million (2016-2021)
  • Table 48. Japan Brain Biomarker, by Application USD Million (2016-2021)
  • Table 49. Japan Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 50. Japan Brain Biomarker, by End User USD Million (2016-2021)
  • Table 51. India Brain Biomarker, by Type USD Million (2016-2021)
  • Table 52. India Brain Biomarker, by Application USD Million (2016-2021)
  • Table 53. India Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 54. India Brain Biomarker, by End User USD Million (2016-2021)
  • Table 55. South Korea Brain Biomarker, by Type USD Million (2016-2021)
  • Table 56. South Korea Brain Biomarker, by Application USD Million (2016-2021)
  • Table 57. South Korea Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 58. South Korea Brain Biomarker, by End User USD Million (2016-2021)
  • Table 59. Taiwan Brain Biomarker, by Type USD Million (2016-2021)
  • Table 60. Taiwan Brain Biomarker, by Application USD Million (2016-2021)
  • Table 61. Taiwan Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 62. Taiwan Brain Biomarker, by End User USD Million (2016-2021)
  • Table 63. Australia Brain Biomarker, by Type USD Million (2016-2021)
  • Table 64. Australia Brain Biomarker, by Application USD Million (2016-2021)
  • Table 65. Australia Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 66. Australia Brain Biomarker, by End User USD Million (2016-2021)
  • Table 67. Rest of Asia-Pacific Brain Biomarker, by Type USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Brain Biomarker, by Application USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Brain Biomarker, by End User USD Million (2016-2021)
  • Table 71. Europe Brain Biomarker, by Country USD Million (2016-2021)
  • Table 72. Europe Brain Biomarker, by Type USD Million (2016-2021)
  • Table 73. Europe Brain Biomarker, by Application USD Million (2016-2021)
  • Table 74. Europe Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 75. Europe Brain Biomarker, by End User USD Million (2016-2021)
  • Table 76. Germany Brain Biomarker, by Type USD Million (2016-2021)
  • Table 77. Germany Brain Biomarker, by Application USD Million (2016-2021)
  • Table 78. Germany Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 79. Germany Brain Biomarker, by End User USD Million (2016-2021)
  • Table 80. France Brain Biomarker, by Type USD Million (2016-2021)
  • Table 81. France Brain Biomarker, by Application USD Million (2016-2021)
  • Table 82. France Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 83. France Brain Biomarker, by End User USD Million (2016-2021)
  • Table 84. Italy Brain Biomarker, by Type USD Million (2016-2021)
  • Table 85. Italy Brain Biomarker, by Application USD Million (2016-2021)
  • Table 86. Italy Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 87. Italy Brain Biomarker, by End User USD Million (2016-2021)
  • Table 88. United Kingdom Brain Biomarker, by Type USD Million (2016-2021)
  • Table 89. United Kingdom Brain Biomarker, by Application USD Million (2016-2021)
  • Table 90. United Kingdom Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 91. United Kingdom Brain Biomarker, by End User USD Million (2016-2021)
  • Table 92. Netherlands Brain Biomarker, by Type USD Million (2016-2021)
  • Table 93. Netherlands Brain Biomarker, by Application USD Million (2016-2021)
  • Table 94. Netherlands Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 95. Netherlands Brain Biomarker, by End User USD Million (2016-2021)
  • Table 96. Rest of Europe Brain Biomarker, by Type USD Million (2016-2021)
  • Table 97. Rest of Europe Brain Biomarker, by Application USD Million (2016-2021)
  • Table 98. Rest of Europe Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 99. Rest of Europe Brain Biomarker, by End User USD Million (2016-2021)
  • Table 100. MEA Brain Biomarker, by Country USD Million (2016-2021)
  • Table 101. MEA Brain Biomarker, by Type USD Million (2016-2021)
  • Table 102. MEA Brain Biomarker, by Application USD Million (2016-2021)
  • Table 103. MEA Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 104. MEA Brain Biomarker, by End User USD Million (2016-2021)
  • Table 105. Middle East Brain Biomarker, by Type USD Million (2016-2021)
  • Table 106. Middle East Brain Biomarker, by Application USD Million (2016-2021)
  • Table 107. Middle East Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 108. Middle East Brain Biomarker, by End User USD Million (2016-2021)
  • Table 109. Africa Brain Biomarker, by Type USD Million (2016-2021)
  • Table 110. Africa Brain Biomarker, by Application USD Million (2016-2021)
  • Table 111. Africa Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 112. Africa Brain Biomarker, by End User USD Million (2016-2021)
  • Table 113. North America Brain Biomarker, by Country USD Million (2016-2021)
  • Table 114. North America Brain Biomarker, by Type USD Million (2016-2021)
  • Table 115. North America Brain Biomarker, by Application USD Million (2016-2021)
  • Table 116. North America Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 117. North America Brain Biomarker, by End User USD Million (2016-2021)
  • Table 118. United States Brain Biomarker, by Type USD Million (2016-2021)
  • Table 119. United States Brain Biomarker, by Application USD Million (2016-2021)
  • Table 120. United States Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 121. United States Brain Biomarker, by End User USD Million (2016-2021)
  • Table 122. Canada Brain Biomarker, by Type USD Million (2016-2021)
  • Table 123. Canada Brain Biomarker, by Application USD Million (2016-2021)
  • Table 124. Canada Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 125. Canada Brain Biomarker, by End User USD Million (2016-2021)
  • Table 126. Mexico Brain Biomarker, by Type USD Million (2016-2021)
  • Table 127. Mexico Brain Biomarker, by Application USD Million (2016-2021)
  • Table 128. Mexico Brain Biomarker, by Disease USD Million (2016-2021)
  • Table 129. Mexico Brain Biomarker, by End User USD Million (2016-2021)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Brain Biomarker: by Type(USD Million)
  • Table 141. Brain Biomarker Biomarker Test Kits , by Region USD Million (2022-2027)
  • Table 142. Brain Biomarker Biomarker Analyzers , by Region USD Million (2022-2027)
  • Table 143. Brain Biomarker: by Application(USD Million)
  • Table 144. Brain Biomarker Diagnosis , by Region USD Million (2022-2027)
  • Table 145. Brain Biomarker Monitoring , by Region USD Million (2022-2027)
  • Table 146. Brain Biomarker Detect the Patients Response , by Region USD Million (2022-2027)
  • Table 147. Brain Biomarker Other , by Region USD Million (2022-2027)
  • Table 148. Brain Biomarker: by Disease(USD Million)
  • Table 149. Brain Biomarker Alzheimer’s Disease , by Region USD Million (2022-2027)
  • Table 150. Brain Biomarker Parkinson’s Disease , by Region USD Million (2022-2027)
  • Table 151. Brain Biomarker Huntington’s Disease , by Region USD Million (2022-2027)
  • Table 152. Brain Biomarker Stroke , by Region USD Million (2022-2027)
  • Table 153. Brain Biomarker Others , by Region USD Million (2022-2027)
  • Table 154. Brain Biomarker: by End User(USD Million)
  • Table 155. Brain Biomarker Hospitals , by Region USD Million (2022-2027)
  • Table 156. Brain Biomarker Research Institutes , by Region USD Million (2022-2027)
  • Table 157. Brain Biomarker Surgical Centres , by Region USD Million (2022-2027)
  • Table 158. Brain Biomarker Diagnostic Centres , by Region USD Million (2022-2027)
  • Table 159. Brain Biomarker Others , by Region USD Million (2022-2027)
  • Table 160. South America Brain Biomarker, by Country USD Million (2022-2027)
  • Table 161. South America Brain Biomarker, by Type USD Million (2022-2027)
  • Table 162. South America Brain Biomarker, by Application USD Million (2022-2027)
  • Table 163. South America Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 164. South America Brain Biomarker, by End User USD Million (2022-2027)
  • Table 165. Brazil Brain Biomarker, by Type USD Million (2022-2027)
  • Table 166. Brazil Brain Biomarker, by Application USD Million (2022-2027)
  • Table 167. Brazil Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 168. Brazil Brain Biomarker, by End User USD Million (2022-2027)
  • Table 169. Argentina Brain Biomarker, by Type USD Million (2022-2027)
  • Table 170. Argentina Brain Biomarker, by Application USD Million (2022-2027)
  • Table 171. Argentina Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 172. Argentina Brain Biomarker, by End User USD Million (2022-2027)
  • Table 173. Rest of South America Brain Biomarker, by Type USD Million (2022-2027)
  • Table 174. Rest of South America Brain Biomarker, by Application USD Million (2022-2027)
  • Table 175. Rest of South America Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 176. Rest of South America Brain Biomarker, by End User USD Million (2022-2027)
  • Table 177. Asia Pacific Brain Biomarker, by Country USD Million (2022-2027)
  • Table 178. Asia Pacific Brain Biomarker, by Type USD Million (2022-2027)
  • Table 179. Asia Pacific Brain Biomarker, by Application USD Million (2022-2027)
  • Table 180. Asia Pacific Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 181. Asia Pacific Brain Biomarker, by End User USD Million (2022-2027)
  • Table 182. China Brain Biomarker, by Type USD Million (2022-2027)
  • Table 183. China Brain Biomarker, by Application USD Million (2022-2027)
  • Table 184. China Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 185. China Brain Biomarker, by End User USD Million (2022-2027)
  • Table 186. Japan Brain Biomarker, by Type USD Million (2022-2027)
  • Table 187. Japan Brain Biomarker, by Application USD Million (2022-2027)
  • Table 188. Japan Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 189. Japan Brain Biomarker, by End User USD Million (2022-2027)
  • Table 190. India Brain Biomarker, by Type USD Million (2022-2027)
  • Table 191. India Brain Biomarker, by Application USD Million (2022-2027)
  • Table 192. India Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 193. India Brain Biomarker, by End User USD Million (2022-2027)
  • Table 194. South Korea Brain Biomarker, by Type USD Million (2022-2027)
  • Table 195. South Korea Brain Biomarker, by Application USD Million (2022-2027)
  • Table 196. South Korea Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 197. South Korea Brain Biomarker, by End User USD Million (2022-2027)
  • Table 198. Taiwan Brain Biomarker, by Type USD Million (2022-2027)
  • Table 199. Taiwan Brain Biomarker, by Application USD Million (2022-2027)
  • Table 200. Taiwan Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 201. Taiwan Brain Biomarker, by End User USD Million (2022-2027)
  • Table 202. Australia Brain Biomarker, by Type USD Million (2022-2027)
  • Table 203. Australia Brain Biomarker, by Application USD Million (2022-2027)
  • Table 204. Australia Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 205. Australia Brain Biomarker, by End User USD Million (2022-2027)
  • Table 206. Rest of Asia-Pacific Brain Biomarker, by Type USD Million (2022-2027)
  • Table 207. Rest of Asia-Pacific Brain Biomarker, by Application USD Million (2022-2027)
  • Table 208. Rest of Asia-Pacific Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 209. Rest of Asia-Pacific Brain Biomarker, by End User USD Million (2022-2027)
  • Table 210. Europe Brain Biomarker, by Country USD Million (2022-2027)
  • Table 211. Europe Brain Biomarker, by Type USD Million (2022-2027)
  • Table 212. Europe Brain Biomarker, by Application USD Million (2022-2027)
  • Table 213. Europe Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 214. Europe Brain Biomarker, by End User USD Million (2022-2027)
  • Table 215. Germany Brain Biomarker, by Type USD Million (2022-2027)
  • Table 216. Germany Brain Biomarker, by Application USD Million (2022-2027)
  • Table 217. Germany Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 218. Germany Brain Biomarker, by End User USD Million (2022-2027)
  • Table 219. France Brain Biomarker, by Type USD Million (2022-2027)
  • Table 220. France Brain Biomarker, by Application USD Million (2022-2027)
  • Table 221. France Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 222. France Brain Biomarker, by End User USD Million (2022-2027)
  • Table 223. Italy Brain Biomarker, by Type USD Million (2022-2027)
  • Table 224. Italy Brain Biomarker, by Application USD Million (2022-2027)
  • Table 225. Italy Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 226. Italy Brain Biomarker, by End User USD Million (2022-2027)
  • Table 227. United Kingdom Brain Biomarker, by Type USD Million (2022-2027)
  • Table 228. United Kingdom Brain Biomarker, by Application USD Million (2022-2027)
  • Table 229. United Kingdom Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 230. United Kingdom Brain Biomarker, by End User USD Million (2022-2027)
  • Table 231. Netherlands Brain Biomarker, by Type USD Million (2022-2027)
  • Table 232. Netherlands Brain Biomarker, by Application USD Million (2022-2027)
  • Table 233. Netherlands Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 234. Netherlands Brain Biomarker, by End User USD Million (2022-2027)
  • Table 235. Rest of Europe Brain Biomarker, by Type USD Million (2022-2027)
  • Table 236. Rest of Europe Brain Biomarker, by Application USD Million (2022-2027)
  • Table 237. Rest of Europe Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 238. Rest of Europe Brain Biomarker, by End User USD Million (2022-2027)
  • Table 239. MEA Brain Biomarker, by Country USD Million (2022-2027)
  • Table 240. MEA Brain Biomarker, by Type USD Million (2022-2027)
  • Table 241. MEA Brain Biomarker, by Application USD Million (2022-2027)
  • Table 242. MEA Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 243. MEA Brain Biomarker, by End User USD Million (2022-2027)
  • Table 244. Middle East Brain Biomarker, by Type USD Million (2022-2027)
  • Table 245. Middle East Brain Biomarker, by Application USD Million (2022-2027)
  • Table 246. Middle East Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 247. Middle East Brain Biomarker, by End User USD Million (2022-2027)
  • Table 248. Africa Brain Biomarker, by Type USD Million (2022-2027)
  • Table 249. Africa Brain Biomarker, by Application USD Million (2022-2027)
  • Table 250. Africa Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 251. Africa Brain Biomarker, by End User USD Million (2022-2027)
  • Table 252. North America Brain Biomarker, by Country USD Million (2022-2027)
  • Table 253. North America Brain Biomarker, by Type USD Million (2022-2027)
  • Table 254. North America Brain Biomarker, by Application USD Million (2022-2027)
  • Table 255. North America Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 256. North America Brain Biomarker, by End User USD Million (2022-2027)
  • Table 257. United States Brain Biomarker, by Type USD Million (2022-2027)
  • Table 258. United States Brain Biomarker, by Application USD Million (2022-2027)
  • Table 259. United States Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 260. United States Brain Biomarker, by End User USD Million (2022-2027)
  • Table 261. Canada Brain Biomarker, by Type USD Million (2022-2027)
  • Table 262. Canada Brain Biomarker, by Application USD Million (2022-2027)
  • Table 263. Canada Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 264. Canada Brain Biomarker, by End User USD Million (2022-2027)
  • Table 265. Mexico Brain Biomarker, by Type USD Million (2022-2027)
  • Table 266. Mexico Brain Biomarker, by Application USD Million (2022-2027)
  • Table 267. Mexico Brain Biomarker, by Disease USD Million (2022-2027)
  • Table 268. Mexico Brain Biomarker, by End User USD Million (2022-2027)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Brain Biomarker: by Type USD Million (2016-2021)
  • Figure 5. Global Brain Biomarker: by Application USD Million (2016-2021)
  • Figure 6. Global Brain Biomarker: by Disease USD Million (2016-2021)
  • Figure 7. Global Brain Biomarker: by End User USD Million (2016-2021)
  • Figure 8. South America Brain Biomarker Share (%), by Country
  • Figure 9. Asia Pacific Brain Biomarker Share (%), by Country
  • Figure 10. Europe Brain Biomarker Share (%), by Country
  • Figure 11. MEA Brain Biomarker Share (%), by Country
  • Figure 12. North America Brain Biomarker Share (%), by Country
  • Figure 13. Global Brain Biomarker share by Players 2021 (%)
  • Figure 14. Global Brain Biomarker share by Players (Top 3) 2021(%)
  • Figure 15. Global Brain Biomarker share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Advanced Brain Monitoring Revenue, Net Income and Gross profit
  • Figure 18. Advanced Brain Monitoring Revenue: by Geography 2021
  • Figure 19. Electrical Geodesics (United States) Revenue, Net Income and Gross profit
  • Figure 20. Electrical Geodesics (United States) Revenue: by Geography 2021
  • Figure 21. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2021
  • Figure 23. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Siemens Healthineers (Germany) Revenue: by Geography 2021
  • Figure 25. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 26. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 27. NeuroVista (United States) Revenue, Net Income and Gross profit
  • Figure 28. NeuroVista (United States) Revenue: by Geography 2021
  • Figure 29. Nexus-DX Revenue, Net Income and Gross profit
  • Figure 30. Nexus-DX Revenue: by Geography 2021
  • Figure 31. Qiagen N.V. (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Qiagen N.V. (Germany) Revenue: by Geography 2021
  • Figure 33. Lifesign LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Lifesign LLC. (United States) Revenue: by Geography 2021
  • Figure 35. BrainScope Revenue, Net Income and Gross profit
  • Figure 36. BrainScope Revenue: by Geography 2021
  • Figure 37. Global Brain Biomarker: by Type USD Million (2022-2027)
  • Figure 38. Global Brain Biomarker: by Application USD Million (2022-2027)
  • Figure 39. Global Brain Biomarker: by Disease USD Million (2022-2027)
  • Figure 40. Global Brain Biomarker: by End User USD Million (2022-2027)
  • Figure 41. South America Brain Biomarker Share (%), by Country
  • Figure 42. Asia Pacific Brain Biomarker Share (%), by Country
  • Figure 43. Europe Brain Biomarker Share (%), by Country
  • Figure 44. MEA Brain Biomarker Share (%), by Country
  • Figure 45. North America Brain Biomarker Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Advanced Brain Monitoring
  • Electrical Geodesics (United States)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Siemens Healthineers (Germany)
  • GE Healthcare (United States)
  • NeuroVista (United States)
  • Nexus-DX
  • Qiagen N.V. (Germany)
  • Lifesign LLC. (United States)
  • BrainScope
Select User Access Type

Key Highlights of Report


Jul 2022 125 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Brain Biomarker Quantitative research analysis
Global Brain Biomarker Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Advanced Brain Monitoring, Electrical Geodesics (United States), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers (Germany), GE Healthcare (United States), NeuroVista (United States), Nexus-DX, Qiagen N.V. (Germany), Lifesign LLC. (United States) and BrainScope etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Investment in The Research of Biomarkers" is seen as one of major influencing trends for Brain Biomarker Market during projected period 2021-2027.
The Brain Biomarker market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Brain Biomarker Report?

Have a Query? Click Here

Other Related Reports

Nutritional Analysis Comprehensive Study by Application (Beverages, Snacks, Bakery & Confectionery, Meat & Poultry, Dairy & Desserts, Edible Fats & Oils, Baby Food, Others (Sauces, Dressings, and Con...
$ 3750
Vortex Mixer Comprehensive Study by Type (Mini Vortex Mixers, Heavy-Duty Vortex Mixers, Microplate Vortex Mixers, Multi-Tube Vortex Mixers), Application (Biochemical Labs, Analytical Labs, Research L...
$ 3450
Mucin 1 Comprehensive Study by Type (TG-4010, GO-2032c, ImMucin, BI-1361849, Others), Application (Prostate Cancer, Breast Cancer, Colon Cancer, Ovarian Cancer, Others) Players and Region - Global Ma...
$ 3500
Protein Production Comprehensive Study by Type (Prokaryotic Systems, Mammalian Cell Systems, Yeast Cell Systems, Insect Cell Systems, Cell-Free Systems, Algal-Based Systems, Others), Application (Com...
$ 3750
Recombinant Human EGF Comprehensive Study by Application (Pharmaceuticals, Cosmetics, Others), Category (Heparin-binding EGF-like growth factor (HB-EGF), Amphiregulin (AR), Epiregulin (EPR), Transfor...
$ 3750
Genetic Ancestry Testing Comprehensive Study by Type (Y Chromosome Testing, Mitochondrial DNA Testing, Single Nucleotide Polymorphism Testing), Service (Online Testing, Offline Testing) Players and R...
$ 3500